Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Canagliflozin/Metformin XR FDC vs Individual Components
NCT02077803Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of canagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration of Canagliflozin at Day 4 and Maximum Plasma Concentration of Metformin at Day 3. Started Mar 2014; status: completed.
02
Drugs
canagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02077803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02077803.